| ［1］ |
Ratner M. First PDE4 inhibitor for psoriasis hits the market but impact is uncertain［J］. Nat Biotechnol, 2014,32（6）:505⁃507. doi: 10.1038/nbt0614⁃505.<br />
|
| ［2］ |
Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.<br />
|
| ［3］ |
Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor （apremilast） for atopic dermatitis in adults［J］. Arch Dermatol, 2012,148（8）:890⁃897. doi: 10.1001/archdermatol.2012.812.<br />
|
| ［4］ |
Paul J, Foss CE, Hirano SA, et al. An open⁃label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series［J］. J Am Acad Dermatol, 2013,68（2）:255⁃261. doi: 10.1016/j.jaad.2012.07.014.<br />
|
| ［5］ |
Thompson BJ, Furniss M, Zhao W, et al. An oral phosphodiesterase inhibitor （apremilast） for inflammatory rosacea in adults: a pilot study［J］. JAMA Dermatol, 2014,150（9）:1013⁃1014. doi: 10.1001/ jamadermatol.2013.10526.<br />
|
| ［6］ |
De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open⁃label, single⁃arm, pilot study［J］. J Drugs Dermatol, 2012,11（10）:1224⁃1226.<br />
|
| ［7］ |
Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis［J］. Arch Dermatol, 2012,148（2）:262⁃264. doi: 10.1001/archdermatol.2011.301.<br />
|
| ［8］ |
Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet′s syndrome⁃⁃a phase 2, placebo⁃controlled study［J］. N Engl J Med, 2015,372（16）:1510⁃1518. doi: 10.1056/NEJMoa1408684.<br />
|
| ［9］ |
Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double⁃blind, placebo⁃controlled study［J］. Arthritis Rheum, 2012,64（10）:3156⁃3167. doi: 10.1002/art.34627.<br />
|
| ［10］ |
Keravis T, Monneaux F, Yougbaré I, et al. Disease progression in MRL/lpr lupus⁃prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 （PDE4） inhibitor［J］. PLoS One, 2012,7（1）:e28899. doi: 10.1371/journal.pone.0028899.<br />
|
| ［11］ |
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis［J］. Biochem Pharmacol, 2012,83（12）:1583⁃1590. doi: 10.1016/j.bcp.2012.01.001.<br />
|
| ［12］ |
Türsen B, Güvenç U, Türsen Ü. Apremilast treatment in dermatology［J］. J Turk Acad Dermatol, 2016,10（3）: 16103r1. doi: 10.6003/ jtad.16103r1.<br />
|
| ［13］ |
孙洁,龚春燕. 治疗斑块状银屑病和银屑病关节炎的新药——阿普斯特［J］. 中华皮肤科杂志, 2017,50（2）:145⁃148. doi: 10. 3760/cma.j.issn.0412⁃4030.2017.02.030.<br />
|
| ［14］ |
沈芳, 谢韶琼. 细胞因子与银屑病发病关系的研究进展［J］. 中国麻风皮肤病杂志, 2015,31（3）:156⁃159.<br />
|
| ［15］ |
李红, 胡晋红. 银屑病发病机制的免疫学研究进展［J］. 药学服务与研究, 2012（4）:277⁃279. doi: 10.5428/pcar20120410.<br />
|
| ［16］ |
Gottlieb AB, Strober B, Krueger JG, et al. An open⁃label, single⁃arm pilot study in patients with severe plaque⁃type psoriasis treated with an oral anti⁃inflammatory agent, apremilast［J］. Curr Med Res Opin, 2008,24（5）:1529⁃1538. doi: 10.1185/030079908X 301866.<br />
|
| ［17］ |
Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial［J］. Lancet, 2012,380（9843）:738⁃746. doi: 10.1016/S0140⁃6736（12）60642⁃4.<br />
|
| ［18］ |
Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial［J］. J Dermatol, 2017,44（8）:873⁃884. doi: 10.1111/1346⁃8138.13829.<br />
|
| ［19］ |
Papp KA, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double⁃blind, placebo⁃controlled, parallel⁃group, dose⁃comparison study［J］. J Eur Acad Dermatol Venereol, 2013,27（3）:e376⁃e383. doi: 10.1111/<br />
|
|
j.1468⁃3083.2012.04716.x.<br />
|
| ［20］ |
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.<br />
|
| ［21］ |
Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis［J］. Rheum Dis Clin North Am, 2015,41（4）:643⁃663. doi: 10.1016/j.rdc.2015.07.006.<br />
|
| ［22］ |
Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014,73（6）:1020⁃1026. doi: 10.1136/annrheumdis⁃ 2013⁃205056.<br />
|
| ［23］ |
Kavanaugh A, Gladman DD, Gomez⁃Reino JJ. Durability of apremilast response in patients with psoriatic arthritis: long⁃term （208⁃week） results from the palace 1 trial. Annals of the rheumatic diseases［J］. European Congress of Rheumatology, 2017. doi: 10. 1136/annrheumdis⁃2017⁃eular.3001.<br />
|
| ［24］ |
Saporito RC, Cohen DJ. Apremilast use for moderate⁃to⁃severe atopic dermatitis in pediatric patients［J］. Case Rep Dermatol, 2016,8（2）:179⁃184. doi: 10.1159/000446836.<br />
|
| ［25］ |
Abrouk M, Farahnik B, Zhu TH, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses［J］. J Am Acad Dermatol, 2017,77（1）:177⁃180. doi: 10.1016/j.jaad.2017. 03.020.<br />
|
| ［26］ |
Volf EM, Au SC, Dumont N, et al. A phase 2, open⁃label, investigator⁃initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis［J］. J Drugs Dermatol, 2012,11（3）:341⁃346.<br />
|
| ［27］ |
Yougbare I, Boire G, Roy M, et al. NCS 613 exhibits anti⁃inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF⁃kappaB signalling pathways while reducing proinflammatory cytokine production［J］. Can J Physiol Pharmacol, 2013,91（5）:353⁃361. doi: 10.1139/cjpp⁃2012⁃0233.<br />
|
| ［28］ |
Tulunay A, Dozmorov MG, Ture⁃Ozdemir F, et al. Activation of the JAK/STAT pathway in Behcet′s disease［J］. Genes Immun, 2015,16（2）:170⁃175. doi: 10.1038/gene.2014.64.<br />
|
| ［29］ |
Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.<br />
|
| ［30］ |
Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata［J］. J Am Acad Dermatol, 2017,77（4）:773⁃774. doi: 10.1016/j.jaad.2017.05.034.<br />
|
| ［31］ |
王岚琦, 鞠强. 玫瑰痤疮发生的免疫学研究进展［J］. 中华皮肤科杂志, 2017 , 50 （3）:219⁃221. doi: 10.3760/cma.j.issn.0412⁃4030.<br />
|
| 20 |
17.03. 018.<br />
|
